Literature DB >> 6966182

Comparison of immune derangements in patients with different malignancies.

A Lichtenstein, J Zighelboim, F Dorey, S Brossman, J L Fahey.   

Abstract

Immune function was evaluated in 109 patients with carcinoma of the breast, bladder, head and neck, and lung. Patients with head and neck cancer showed the most profound derangements of immune function; patients with lung cancer showed no detectable abnormalities. Non-irradiated patients with disseminated head and neck cancer had significantly depressed lymphocyte counts (mean 1357/mm3, P less than .05), E-rosette forming cells (mean 770/mm3, P less than .05), and response to phytohemagglutinin (P less than .05) as compared to controls. This immunodeficiency was detected in patients with localized as well as advanced disease. Although significant differences were noted between patients with head and neck cancer and the other tumors, these differences were minimized by radiation therapy. All irradiated patients showed comparable degrees of immune dysfunction. Absolute Fc-receptor cells were depressed in all irradiated patients and in non-irradiated patients with disseminated breast cancer.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6966182     DOI: 10.1002/1097-0142(19800415)45:8<2090::aid-cncr2820450816>3.0.co;2-o

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

1.  Defective monocyte chemotaxis in patients with epidermoid tumors of the head and neck.

Authors:  A Güngör; S Yetgin; B Sözeri
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

2.  Responses of killer cells in head and neck cancer patients.

Authors:  S Fujieda; H Saito; T Hoshino
Journal:  Eur Arch Otorhinolaryngol       Date:  1990       Impact factor: 2.503

3.  Enhancement of delayed cutaneous hypersensitivity in untreated cancer patients given a short-term oral treatment with C 1821.

Authors:  J M Lang; C Giron; A Aleksijevic; C Marchiani; R Zalisz; F Oberling
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

4.  Difference in effect of single immunosuppressive agents (cyclophosphamide, CCNU, 5-FU) on peripheral blood immune cell parameters and central nervous system immunoglobulin synthesis rate in patients with multiple sclerosis.

Authors:  W W Shih; R W Baumhefner; W W Tourtellotte; C M Haskell; E L Korn; J L Fahey
Journal:  Clin Exp Immunol       Date:  1983-07       Impact factor: 4.330

5.  Inhibition of lymphocyte response by prostaglandin-producing suppressor cells in patients with melanoma.

Authors:  J L Murray; G M Kollmorgen
Journal:  J Clin Immunol       Date:  1983-07       Impact factor: 8.317

6.  Peripheral blood and tumor-infiltrating mononuclear cell analysis in esophagus and head and neck cancer.

Authors:  P Lozac'h; P Corbeau; C Zabbe; J F Charles; P Youinou
Journal:  Med Oncol Tumor Pharmacother       Date:  1987

7.  Estimation of Circulating Immune Complexes in patients with Oral Leukoplakia and Oral Submucous Fibrosis: A Case Control Study.

Authors:  Maheswari H; Eswaran M A; Srividhya S; Malavika R; Prabhu R; Geetha K R
Journal:  J Clin Diagn Res       Date:  2014-01-12

8.  Serum immunoglobulins in patients with carcinoma of the oral cavity, uterine cervix and breast.

Authors:  T Vijayakumar; R Ankathil; P Remani; V K Sasidharan; K K Vijayan; D M Vasudevan
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

9.  Depressed monocyte polarization and clustering of dendritic cells in patients with head and neck cancer: in vitro restoration of this immunosuppression by thymic hormones.

Authors:  M P Tas; P J Simons; F J Balm; H A Drexhage
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

10.  Circulating immune complexes and trace elements (Copper, Iron and Selenium) as markers in oral precancer and cancer : a randomised, controlled clinical trial.

Authors:  Sunali S Khanna; Freny R Karjodkar
Journal:  Head Face Med       Date:  2006-10-16       Impact factor: 2.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.